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Summary Acute vasodilator tests with prostacyclin (PGI2) or inhaled nitric oxide
(iNO) are used to select patients with pulmonary arterial hypertension (PAH) who
should be treated with oral vasodilators. The haemodynamic effects of PGI2 and iNO
are different, and the limits for considering a vasodilator response as significant are
controversial. The study was aimed to investigate the diagnostic performance of
acute vasodilator testing with iNO and PGI2 in predicting the clinical outcome after 1
year treatment with oral vasodilators. Twenty-seven patients with severe PAH were
studied. Nineteen patients were treated with oral vasodilators and their outcome
after 1 year was qualified as favourable or unfavourable. The diagnostic performance
of vasodilator tests in predicting this outcome was evaluated using receiver
operating characteristics (ROC) curves. The acute effects of iNO and PGI2 on
pulmonary artery pressure (PAP) were similar. By contrast, PGI2 produced more
marked changes on cardiac output and pulmonary vascular resistance than iNO
(Po0:05). The evolution at 1 year was favourable in 11 patients and unfavourable in
8. Patients with favourable evolution showed greater decrease of PAP with iNO than
with PGI2 (Po0:05). The decrease of PAP with iNO had the greatest predictive value
on the clinical outcome (area under ROC curve, 0.83). We conclude that in patients
with PAH, acute vasodilator testing with iNO is preferable to PGI2 because it reflects
more consistently the changes in pulmonary vascular tone. The acute decrease of
PAP with iNO is the best predictor of the long-term response to oral vasodilator
treatment.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Patients with pulmonary arterial hypertension
(PAH) who show vasodilator responsiveness at the
time of diagnosis have better survival than their
counterparts when treated chronically with oral
vasodilators.1–4 For this reason acute vasoreactivity
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testing is the first step in the current algorithm for
the treatment of this condition.5–7 However, there
is no full agreement on the interpretation of the
results of acute vasodilator testing. In addition,
vasodilator agents may elicit different patterns of
response in terms of the effects on pulmonary
artery pressure (PAP), cardiac output and pulmon-
ary vascular resistance (PVR).8,9 The clinical sig-
nificance of these different patterns of response is
uncertain and there is no consensus in the criteria
used to consider an acute vasodilator response as
significant.4,10,11
Further, different agents have been used for
acute vasodilator testing, the most commonly
employed of which are intravenous prostacyclin
(PGI2),
12,13 inhaled nitric oxide (iNO)14–16 and
intravenous adenosin monophosphate.17,18 The
ability of each of these agents to identify patients
who will respond favourably to chronic treatment
with oral vasodilators has been assumed to be the
same.5,6 However, the acute haemodynamic effects
of each agent are different, especially with respect
to the cardiac function and the calculated
PVR.12,14,15 Accordingly, the specific haemodynamic
profile of response elicited by each agent might
influence the results of the acute vasoreactivity
test, and hence their interpretation.
The results of acute vasodilator testing have
not been fully validated in terms of their diagno-
stic accuracy in detecting those patients who will
show favourable evolution on the long term
with oral vasodilator treatment (i.e. calcium
channel blockers). This is important since
these patients may obtain clinical benefit
from oral vasodilators without the need to undergo
other treatments that need permanent intrave-
nous access, are much more expensive or
have a less known safety profile.19 Accordingly,
the aims of this study were to compare the acute
vasodilator response to iNO and i.v. PGI2 in
patients with PAH, and to analyse the diagnostic
performance of each agent in predicting the
clinical outcome after 1-year treatment with oral
vasodilators.
Methods
Subjects
We studied prospectively 27 patients who under-
went right heart catheterisation for the diagnosis of
pulmonary hypertension. All of them had a previous
echocardiography showing increased systolic pul-
monary arterial pressure (440mmHg). They were
diagnosed of PAH, either primary or associated with
another condition,5 using conventional criteria.
The patient group consisted of 17 women and 10
men with a mean age of 37713 years. The majority
of patients were in class II or III of the modified New
York Heart Association (NYHA) classification.5 Clin-
ical characteristics of the patients are shown in
Table 1.
Study design
A complete initial baseline haemodynamic evalua-
tion was performed in supine position, breathing
room air in all but one case, and after all
vasodilating agents had been discontinued for at
least 48 h before the study. After venous access was
achieved through the internal jugular vein, pul-
monary artery catheterisation was performed by
means of a 7F triple lumen flow-directed thermo-
dilution catheter (Baxter, Irvine, CA, USA), which
was advanced by pressure wave monitoring. Trans-
ducers were positioned at the anterior axillary line
level, zeroed at the atmospheric pressure, and PAP
was continuously monitored (M1006A, Hewlett-
Packard, Boeblingen, Germany). Cardiac output
was determined in triplicate by the thermodilution
technique (M1012A, Hewlett-Packard). Because
pulmonary capillary wedge pressure could not be
recorded in two patients, total pulmonary vascular
resistance (TPVR) was considered for the purposes
of the present study. An arterial line was inserted in
the radial artery (Plastimed, Saint-Leu-La-F #oret,
Cedex, France) for continuous systemic arterial
pressure monitoring (M1006A, Hewlett-Packard)
and arterial blood gas analysis. Trascutaneous
arterial oxyhaemoglobin saturation was continu-
ously monitored by pulse oximetry (M1020A, Hew-
lett-Packard). Arterial and mixed-venous blood
samples were collected simultaneously for the
determination of pH, CO2 and O2 tensions, oxyhae-
moglobin saturation, and haemoglobin and methae-
moglobin concentrations (Ciba-Corning 800,
Medfield, MA, USA).
Acute vasodilator test
After a duplicate set of baseline measurements,
taken more than 20min apart, the responses to
iNO and i.v. PGI2 were studied sequentially.
Initially, patients breathed a mixture of NO
in air from a Douglas bag using an unidirectional
valve (Hans Rudolph, Kansas city, MO, USA) for
20min, as previously described.20,21 Haemody-
namic measurements were performed at the end
of the inhalation period and the concentration of
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NO was increased progressively (10, 20, and 40
parts per million) until a significant response was
achieved (see below).
After a washout period of 20min, and after
ensuring return to baseline haemodynamic values,
an infusion of PGI2 (Flolant, Glaxo-Wellcome,
Madrid, Spain) was administered. The infusion rate
was started at 2 ng/kg/min and increased stepwise
by 2 ng/kg/min increments every 15min up to a
maximal dose of 12 ng/kg/min, until a significant
response was obtained, or the patient developed
symptoms of intolerance.
The vasodilator response to either iNO or PGI2
was considered significant when TPVR decreased by
more than 30% and PAP by more than 20% of the
respective pre-treatment values. Arterial and
mixed-venous bloods were sampled at the highest
concentrations of NO and PGI2 for respiratory gas
analysis.
Chronic treatment
Chronic treatment was established according to the
acute response to i.v. PGI2. Patients who showed a
decrease in TPVR greater than 20% of the baseline
value3,22 and had a cardiac index greater than 2 l/
min/m2, were treated with oral vasodilators:
calcium channel blockers (nifedipine or diltiazem)
or isosorbide mononitrate. The latter was em-
ployed in patients with portopulmonary hyperten-
sion.23 In the remaining cases, i.e. those who
showed a TPVR decrease with PGI2 lower than 20%
from baseline or the cardiac index was always
lower than 2 l/min/m2,6 we initiated a continuous
infusion of intravenous epoprostenol.
The clinical outcome of chronic treatment with
oral vasodilators was analysed after 12 months
and qualified as favourable or unfavourable. A
favourable outcome was considered when NYHA
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Table 1 Clinical characteristics and baseline haemodynamic findings.
Age, yr 37713
Female/male ratio 17/10
Diagnosis
Primary pulmonary hypertension 13
Pulmonary arterial hypertension associated with
Portal hypertension 5
Collagen vascular disease 7
HIV infection 2
Functional class NYHA
II 11
III 13
IV 3
Baseline haemodynamics
PAP (mmHg) 50711
PCWP (mmHg)n 573
CI (l/min/m2) 2.2370.60
SV (ml) 49717
TPVR (dyn s/cm5) 11617440
RAP (mmHg) 776
SVR (dyns/cm5) 19337661
PaO2 (mmHg) 79735
AaPO2 (mmHg) 41717
PvO2 (mmHg) 3375
SvO2 (%) 64710
Results are given as mean7SD. Definition of abbreviations: NYHA, New York Heart Association; PAP, mean pulmonary artery
pressure; PCWP, pulmonary capillary wedge pressure; CI, cardiac index; SV, stroke volume; TPVR, total pulmonary vascular
resistance; RAP, right atrial pressure; SVR, systemic vascular resistance; PaO2, partial pressure of arterial oxygen; AaPO2,
alveolar to arterial PO2 gradient; PvO2, partial pressure of oxygen in mixed-venous blood; SvO2, mixed-venous oxygen
saturation.
nn ¼ 25:
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functional class decreased by one or more grades
and the echocardiographyc study showed a reduc-
tion in tricuspid jet velocity, as compared with pre-
treatment values. An unfavourable outcome was
considered when the above criteria were not
fulfilled, the patient died, or oral vasodilator
treatment was discontinued because of the need
for lung transplantation or continuous intravenous
epoprostenol therapy.
Statistical analysis
All results are expressed as mean7SD. Changes in
the acute vasodilator test were assessed with
paired student’s t-test. Comparisons between
groups were performed using unpaired student’s
t-test. The diagnostic performance of the acute
vasodilator test in predicting the outcome of
chronic oral vasodilator treatment was evaluated
using receiver operating characteristics (ROC)
curves.24,25 All tests were performed using the
SPSS statistical package and P values o0:05 were
considered as significant in all cases.
Results
Study group
Clinical characteristics and baseline haemodynamic
results of the 27 patients are shown in Table 1.
Overall patients had severe pulmonary hyperten-
sion with a mean PAP of 50711mmHg and TPVR of
1161 dynes s/cm5. At baseline, 11 patients had a
cardiac index less than 2 l/min/m2. Eight patients
were initially treated with continuous epoprostenol
infusion. The remaining 19 patients received oral
vasodilators.
Acute vasodilator testing
The results of acute vasodilator test with iNO and
PGI2 are shown in Table 2. PAP decreased signifi-
cantly with the administration of both iNO and
PGI2, being the percent change from baseline the
same with both agents (13%). By contrast, TPVR,
which was also reduced by both agents, decreased
to a greater extent with PGI2 (31712% from
baseline) than with iNO (21717%), the difference
between them being statistically significant
(Po0:05). This was because the cardiac output
increased more markedly when PGI2 was adminis-
tered (þ 34721%) as compared with iNO
(þ 12711%) (Po0:05). The differences in cardiac
output during vasodilator administration resulted
mainly from a greater effect of PGI2 on heart rate
(Table 2). As expected, systemic vascular resis-
tance decreased with the administration of PGI2,
whereas it remained essentially unaltered during
NO inhalation (34% and 6% from baseline, PGI2
and iNO, respectively; Po0:05). During PGI2 infu-
sion and NO inhalation there was a moderate
decrease in arterial PO2 that did not reach
statistical significance. By contrast, mixed-venous
PO2 increased slightly but significantly with the
administration of both agents.
The changes in PAP induced by iNO and PGI2
correlated significantly (r ¼ 0:57; Po0:01),
although with substantial scatter (Fig. 1). Changes
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Table 2 Haemodynamic findings during acute vasodilator testing with inhaled NO and prostacyclin.
Baseline iNO Prostacyclin
PAP (mmHg) 50711 44714n 45712n
% change 13715 1379
TPVR (dyn s/cm5) 11617440 9197430n 8017340n,w
% change 21717 31712w
CI (l/min/m2) 2.2370.60 2.4870.61n 2.9470.76n,w
% change 12711 34721w
SV (ml) 49717 57721n 59721n
HR (min1) 79715 77717 86716n,w
SVR (dyn s/cm5) 19937661 18067673n 12377323n,w
% change 6710 34711w
PaO2 (mmHg) 79735 74718 72722
PvO2 (mmHg) 3375 3576
n 3675n
Results are given as mean7SD.
Definition of abbreviations: see Table 1. iNO, inhaled nitric oxide; HR, heart rate.
nPo0:05 compared with baseline.
wPo0:05 compared with iNO.
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in TPVR induced by both agents also correlated
significantly (r ¼ 0:56; Po0:01), yet the majority of
plots lied above the identity line, due to the
greater effect of PGI2 on TPVR (Fig. 1). Seven
patients reached the initial criteria for a significant
vasodilator response (decrease in TPVR430% and in
PAP420%) with iNO, and seven cases with PGI2,
these results being significantly associated (Fisher
exact test, P ¼ 0:03). Nevertheless, only four
patients fulfilled the criteria for significant vasodi-
lator response with both agents. Three patients
responded only to iNO, and other three responded
only to PGI2.
Long-term response to oral vasodilator
treatment
According to the criteria previously established
(decrease in TPVR o20% or cardiac index o2 l/
min/m2), eight patients (30%) were initially treated
with continuous epoprostenol infusion. The remain-
ing 19 patients received oral vasodilator treatment:
nifedipine, 12 patients; diltiazem, three patients;
and isosorbide mononitrate, four patients. Patients
receiving oral vasodilators were followed for a
mean of 3727104 days. At the end of this period
the mean daily doses of the vasodilator drugs were:
nifedipine, 80726mg; diltiazem, 330752mg; and
isosorbide mononitrate, 93723mg. The clinical
outcome after 1-year treatment was qualified as
favourable in 11 patients (41% of the whole group)
and unfavourable in eight (Fig. 2). Reasons of
unfavourable outcome were death in three cases,
need for transplantation in one case, need of
prostacyclin therapy in one case, and lack of
clinical improvement in three cases. On average,
patients with unfavourable outcome were followed
during 335756 days, and those with favourable
outcome for 395756 days.
Baseline haemodynamics and acute responses to
iNO and PGI2 in patients grouped according to
chronic treatment and clinical outcome are shown
in Table 3. Pulmonary haemodynamics at baseline
did not differ between patients with favourable
and unfavourable outcomes with oral vasodilators.
When tested with iNO, patients who had favourable
evolution had lower PAP and TPVR, and greater
cardiac index, than those with unfavourable evolu-
tion (Table 3). The percent change from baseline of
PAP was significantly greater in the group with
favourable outcome, and there was also a trend for
a greater decrease in TPVR in this group (P ¼ 0:06).
By contrast, when tested with PGI2, patients with
favourable and unfavourable outcomes only dif-
fered in the cardiac index (Table 3). Patients who
underwent continuous epoprostenol treatment had
greater impairment in pulmonary haemodynamics
at baseline, and the haemodynamic changes eli-
cited by both iNO and PGI2 were significantly lower
than in the group who responded favourably to oral
vasodilators (Table 3). Interestingly, compared with
patients with unfavourable responses to oral
vasodilators, those treated with epoprostenol only
differed in the magnitude of change in PAP and in
the value of TPVR during iNO administration.
The diagnostic accuracy of the results obtained
in the acute vasodilator tests with iNO and PGI2 in
predicting a favourable outcome after 1-year
treatment with oral vasodilators was assessed using
ROC curve analysis. Figure 3 shows the ROC curves
for the changes in PAP, TPVR and cardiac index
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Figure 1 Graphs comparing pulmonary haemodynamic responses elicited by iNO and prostacyclin. Left panel.
Comparison of percent change in mean PAP (r ¼ 0:57; Po0:001). Right panel. Comparison of percent change in TPVR
(r ¼ 0:56; Po0:001).
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Figure 2 Clinical outcome after 1-year treatment with oral vasodilators. Panel A. Change in NYHA functional class from
baseline (BSL) to follow-up (F.U.) in patients treated with oral vasodilators with favourable and unfavourable outcomes.
Panel B. Individual changes in systolic PAP measured by echocardiography.
Table 3 Baseline haemodynamics and acute response to vasodilators according to chronic treatment and clinical
outcome at 12 months.
Oral vasodilator
Favourable Unfavourable Epoprostenol
(n ¼ 11) (n ¼ 8) (n ¼ 8)
Baseline haemodynamics
PAP (mmHg) 4579 49715 5678n
TPVR (dyn s/cm5) 9347375 11627470 14727323n
CI (l/min/m2) 2.5170.62 2.0570.50 2.0170.54
SV (ml) 56713 49719 39717n
RAP (mmHg) 574 674 1078
PvO2 (mmHg) 3575 3273 3176
Nitric oxide
PAP (mmHg) 3477 45716n 5877n
DPAP (%) 23715 10710n 175n,w
TPVR (dyn s/cm5) 5927162 9947342n 14037347n,w
DTPVR (%) 32719 18710 7711n
CI (l/min/m2) 2.8270.49 2.2670.50n 2.1970.72n
DCI (%) 15713 11710 7710
Prostacyclin
PAP (mmHg) 3976 44714 55710n
DPAP (%) 1779 1277 7710n
TPVR (dyn s/ cm5) 5747174 8007315 11137310n
DTPVR (%) 36712 3176 25713
CI (l/min/m2) 3.3870.69 2.6470.57n 2.6270.79n
DCI (%) 38724 30712 32723
Results are given as mean7SD.
Definition of abbreviations: see Table 1. D denotes % change from baseline.
nPo0:05 compared with the group with favourable evolution (oral vasodilator).
wPo0:05 compared with the group with unfavourable evolution (oral vasodilator).
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induced by both iNO and PGI2. Statistical analyses
of the area under the ROC curve (AUC) showed that
the decrease in PAP and TPVR induced by iNO had
the greatest diagnostic accuracy in predicting
which patients would respond favourably to oral
vasodilators on the long term, with an AUC of 0.83
and 0.81, respectively (Po0:01 both compared
with a curve with no predictive value, AUC ¼ 0:5)
(Fig. 3). The decrease in PAP induced by PGI2 also
had an acceptable predictive value, with an AUC of
0.73 (Po0:05 compared with AUC ¼ 0:5). By con-
trast, the decrease in TPVR induced by PGI2 did not
have significant predictive value. Similarly, changes
in cardiac index induced by either iNO or PGI2 did
not differ from a test with no predictive value
(Fig. 3).
Discussion
The results of the present study show that in
patients with PAH acute vasodilator testing with
iNO and PGI2 may elicit different haemodynamic
responses, and that the acute response to iNO had
the greatest accuracy in detecting patients who
showed a favourable outcome with chronic treat-
ment with oral vasodilators after 1 year follow-up.
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Figure 3 ROC curves of the results of acute vasodilator testing with iNO (left) and prostacyclin (right) in predicting a
favourable outcome after 1-year treatment with oral vasodilators. ROC curves, and their corresponding area under the
curve (AUC), for the percent change in PAP, TPVR and cardiac index (CI) are shown. The curve for an arbitrary test that
is expected a priori to have no discriminatory value appears as a diagonal line (AUC ¼ 0:5). (*) Denotes that the AUC was
significantly greater than 0.5.
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Inhaled NO and intravenous PGI2 are used
indistinctively as screening agents to assess acute
vasoreactivity in patients with PAH.5 Intravenous
PGI2 has been used for many years due to its potent
vasodilator effect and its rapidity of action.12,13
Inhaled NO was first used in PAH by Pepke-Zaba
et al.26 and introduced as an acute vasodilating
agent more recently by Sitbon et al.14 Compared
with PGI2, iNO has the advantage of a selective
action on pulmonary circulation due to its inactiva-
tion when binded to haemoglobin. Our study
confirms the selective action of iNO on pulmonary
vascular tone with no effect on systemic vascular
resistance (Table 2), in agreement with previous
reports in healthy subjects27 and patients with
different disease conditions,21,28 including patients
with PAH.14,26,29,30 The mean effects of i.v. PGI2 and
iNO on PAP were very similar, although there was
great interindividual variability (Fig. 1). Regarding
TPVR, PGI2 induced a more marked decrease of this
measurement than iNO (Fig. 1, Table 2). The
distinct effects of both drugs on cardiac output
can explain this difference. Whereas cardiac output
increased markedly during PGI2 administration, it
remained practically unaltered during NO inhala-
tion, even in those patients who showed a
significant decrease of PAP. The increase in cardiac
output may explain the reduction in TPVR observed
in some patients who did not show a reduction in
PAP, the so-called ‘‘resistance responders’’.8,9 The
interpretation of this type of response has been
always uncertain, since it may not represent true
vasodilation of the pulmonary vascular bed.8 In
fact, in our study there was a greater number of
‘‘resistance responders’’ when using PGI2 (eight
patients) than when using iNO (2 patients). A
potential explanation for such different effects on
cardiac output could be due to the fact that
systemic hypotension induced by PGI2 can activate
the baroreceptor reflex and produce sympathetic
stimulation of the heart.8 Indeed, in our study
differences in cardiac output were essentially due
to higher heart rate during PGI2 administration
(Table 2). Furthermore, there are some data
suggesting that intravenous PGI2 may exert ino-
tropic effect,31 at least when administered for long
periods of time.32 We think that in our series this
was unlikely because stroke volumes during iNO and
PGI2 administration were very similar and did not
explain the differences in cardiac output.
These findings are relevant regarding the inter-
pretation of acute vasodilator testing in pulmonary
hypertension. The implication is that the agent
used for this purpose may influence the pattern of
response and consequently its interpretation. Ac-
cording to our findings, the reduction of TPVR
elicited by PGI2 appears not to be a reliable marker
of pulmonary vasodilation, as it may be influenced
by systemic hypotension induced by the drug.
Therefore, the use of inhaled NO as screening
vasodilator agent appears to be preferable because
its selective pulmonary action may reflect more
consistently changes in pulmonary vascular tone
and because it does not have inotropic effect.
A second question raised in the present study was
to what extent the acute responses to vasodilator
agents were predictive of the clinical outcome with
oral vasodilator treatment. The criteria to indicate
chronic treatment with oral vasodilators have not
been clearly established and differ among investi-
gators.3,5,10,11,15,22,33 In our study, we indicated
chronic treatment with oral vasodilators in patients
who showed a decrease in TPVR greater that 20%
from baseline when tested with PGI2, as suggested
by others.3,22 Only those patients with a clear
indication for continuous epoprostenol therapy7
were excluded. Furthermore, we evaluated the
clinical evolution after 1 year treatment, a period
of time longer than that used in previous stu-
dies,29,34 thus allowing ample margin for detecting
patients with unfavourable evolution. Our results
indicate that using the criteria of a decrease in
TPVR420%, 40% of the patients showed clinical
improvement after 1-year treatment. Should we
have used more restrictive criteria (i.e. decrease in
PAP420%33 or 410mmHg from baseline5), four of
the 11 patients who showed favourable outcomes
with oral vasodilators would have been considered
‘‘nonresponders’’ and hence candidates to other
treatments (i.e. epoprostenol, bosentan), that
entail greater risk of serious adverse effects and
are much more expensive than oral vasodilators.
To investigate the accuracy of acute vasodilator
test in predicting a favourable outcome we used
ROC curves.24,25 These curves are a useful way to
display the diagnostic performance of a test by
plotting the sensitivity against the false-positive
rate (1-specificity) (Fig. 3). The closer the ROC
curve is to the upper left corner the more accurate
the test is, because the true-positive rate (sensi-
tivity) approximates 1 and the false-positive rate
approximates 0. The global accuracy of the test
was determined by the area under the ROC curve
(AUC). Values of AUC may range from 0.5 (the test
does not have predictive value since it may be
positive or negative at random) to 1 (the test allows
perfect separation of the two groups). Therefore,
the closer the AUC to 1, the greater the accuracy of
the test.25 Furthermore, ROC curves are also useful
to identify ‘‘cut-off’’ values with the best compro-
mise between sensitivity and specificity, as well as
to compare the diagnostic performance of two
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tests. In the present study, changes in PAP and TPVR
induced by iNO had the greatest diagnostic accu-
racy in predicting which patients would respond
favourably to oral vasodilators on the long term,
with AUCs greater than 0.8 (Fig. 3). Therefore,
changes in PAP or TPVR with iNO can be used
indistinctively to assess the reversibility of pulmon-
ary hypertension. The change in PAP induced by
PGI2 also had an acceptable predictive value in
detecting patients with favourable response to oral
vasodilators, with an AUC of 0.73. Nevertheless, its
diagnostic accuracy was lower than that of iNO as
shown by a lower AUC. The greater accuracy of
iNO, as compared with that of i.v. PGI2, could be
explained by its selective action on pulmonary
circulation, which allows better identification of
patients with a vasoconstrictive component in their
pulmonary hypertension, that are more likely to
show a favourable outcome when treated with
drugs that reduce vascular tone. Besides, the
possibility exists that when using PGI2, the increase
in cardiac output that results from its systemic
vasodilator effect, could neutralise the decrease in
PAP induced by the drug. Moreover, the change in
TPVR induced by PGI2 did not have significant
predictive value on the long-term evolution with
oral vasodilators. This finding is consistent with the
fact that the change in TPVR induced by PGI2 is
largely influenced by the change in cardiac output.
Since the change in cardiac output may result not
only from pulmonary vasodilation, but also from
systemic vasodilation, as discussed earlier, it is
likely that the change in TPVR is a poor indicator of
patients with a vasoconstrictive component in their
pulmonary hypertension. Furthermore, in the pre-
sent series changes in cardiac output induced by
either NO or PGI2 did not have predictive value on
the long-term response to chronic vasodilator
treatment. Overall, the ROC analysis indicates that
iNO should be the agent of choice to identify those
patients who are more likely to respond favourably
to chronic treatment with oral vasodilators.
From the ROC curve we identified that a
decrease in PAP induced by iNO greater than 12%
from baseline had a sensitivity of 81% and a
specificity of 86% in detecting patients with
favourable responses on the long term to oral
vasodilator treatment. This ‘‘cut-off’’ point is
lower than the value previously proposed by Rich
et al.33 (a decrease greater than 22%) on the basis
of the spontaneous variability of pulmonary hae-
modynamic measurements. In the study by Rich
et al.33 spontaneous variability was assessed during
a period of 6 h of observation. As already pointed
out by these investigators, measurements carried
out in shorter intervals could be less influenced by
spontaneous variability.33 Indeed, in our series the
mean individual variation between the two sets of
baseline measurements, taken 30min apart, was
4.573.3%. The executive summary of the 1998
World Symposium on Primary Pulmonary Hyperten-
sion5 suggested that the decrease of PAP should be
greater than 10mmHg from baseline, independent
of the vasodilator employed. When using iNO, in
our series this threshold value had a lower
sensitivity (66%) and a similar specificity (85%) than
the threshold of 12%, for detecting patients with
favourable response to oral vasodilators. This
implicates that using the cut-off of 10mmHg, we
would have missed some patients who responded
favourably to oral vasodilators. Accordingly, we
think that considering that iNO is a very specific
vasodilator of pulmonary circulation, it is likely
that a decrease in PAP greater than 12% from
baseline, could be considered as suggestive of a
good clinical response to oral vasodilators. In this
respect, it is of note that a 12% decrease in FEV1 is
currently considered as a significant bronchodilator
response in patients with airway obstruction.35
Nevertheless, this suggestion should be tested in a
more ample population.
In summary, the present study shows that in
patients with PAH acute vasodilator testing with i.v.
PGI2 and inhaled NO elicit different responses on
pulmonary haemodynamics, as a result of their
distinct effects on systemic circulation. Because
iNO is a highly selective vasodilator of pulmonary
circulation, its acute haemodynamic effects allow a
more accurate identification of those patients who
are more likely to respond favourably to chronic
treatment with oral vasodilators.
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